CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 102 enrolled
Drug / intervention
OPC-12759 ophthalmic suspension +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01493180
NCT01493180Phase 2Completed
CompareCT.gov

Exploratory Study of OPC-12759 Ophthalmic Suspension in Patients With Keratoconjunctiva Epithelial Disorder

Otsuka Pharmaceutical Co., Ltd.·interventional·Posted Dec 15, 2011·Updated Mar 10, 2015

In Brief

A Phase 2 clinical trial evaluating OPC-12759 ophthalmic suspension and Sodium hyaluronate ophthalmic solution for Keratoconjunctival Epithelial Disorder. Completed, enrolled 102 participants across 10 sites.

Detailed Summary

The purpose of this study is to evaluate the efficacy of OPC-12759 ophthalmic suspension for patients with keratoconjunctival epithelial disorder compared with sodium hyaluronate. Also, safety of OPC-12759 is to be assessed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKeratoconjunctival Epithelial Disorder
CountriesJapan
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedDec 15, 2011
Enrollment StartDec 1, 2011
Primary CompletionNov 1, 2012
Study CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 14.5 years ago

Interventions

OPC-12759 ophthalmic suspensiondrug

OPC-12759 ophthalmic suspension 2%

Sodium hyaluronate ophthalmic solutiondrug

Sodium hyaluronate ophthalmic solution 0.1%